SMS Pharmaceuticals Limited — Board Meeting, 30-05-2025: Outcome of Board Meeting

SMS Pharmaceuticals has announced a board meeting on its consolidated financial results for the quarter and half-year, reporting a robust net profit of Rs. 67.14 Cr for FY25, up from Rs. 49.82 Cr last year, on revenue of Rs. 782.75 Cr. The Board approved a final dividend of Rs. 0.40 per share. Equity capital rose to Rs. 8.87 Cr following conversion of 40 lakh warrants. New Cost and Secretarial Auditors were appointed, and Internal Auditors re-appointed. The company plans to invest Rs. 10 Cr in its subsidiary SMS Peptides and will launch a new pharma unit targeting greenfield projects in novel therapeutic areas.